A systematic review and meta-analysis from the Harvard T.H. Chan School of Public Health reported a large effect of ...

Adults with attention-deficit/hyperactivity disorder (ADHD) who use an extended-release medication are more likely to ...

Corcept Therapeutics Incorporated (NASDAQ: CORT) has recently submitted a New Drug Application (NDA) to the U.S. Food and ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body ...

Relacorilant has orphan drug designation in the United States and the European Union for the treatment ... cortisol. Symptoms vary, but most patients experience one or more of the following ...

There is a medical condition called Cushing’s syndrome, in which cortisol levels become significantly elevated, either due to overproduction or medication, which can cause a “moon” or ...

You may need a medication that doesn’t require dose adjustment based on your kidney function. Diabetes without proper treatment or management may lead to further complications, one being kidney ...

denying a uniquely vulnerable population access to high-quality care amid the worst drug epidemic in the country’s history. A STAT investigation has found that opposition to medications for ...

Motivated in part by the limitations of existing treatments — mostly involving drugs or talk therapy with a psychologist — many researchers are looking to develop digital tools to treat mental ...

The move aims to increase access to effective but expensive treatments like GLP-1 drugs for millions of Americans with obesity. If finalized, the policy could have a significant impact on public ...

Lenacapavir is already approved for use as a treatment for multi-drug resistant HIV, costing around $42,250 for the first year of therapy in the United States. Clinical trials this year showed it ...

(Photo by Michael M. Santiago/Getty Images) As we look towards 2025, the relatively high valuation of many U.S. stocks may add to investor risk. On most valuation metrics, the U.S. stock market ...